Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy

Balancing safety and efficacy is a major consideration for cancer treatments, especially when combining cancer immunotherapy with other treatment modalities such as chemotherapy. Approaches that induce immunogenic cell death (ICD) are expected to eliminate cancer cells by direct cell killing as well...

Descripción completa

Detalles Bibliográficos
Autores principales: Medrano, Ruan F. V., Salles, Thiago A., Dariolli, Rafael, Antunes, Fernanda, Feitosa, Valker A., Hunger, Aline, Catani, João P. P., Mendonça, Samir A., Tamura, Rodrigo E., Lana, Marlous G., Rodrigues, Elaine G., Strauss, Bryan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365852/
https://www.ncbi.nlm.nih.gov/pubmed/35948616
http://dx.doi.org/10.1038/s41598-022-17775-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365852/
https://www.ncbi.nlm.nih.gov/pubmed/35948616
http://dx.doi.org/10.1038/s41598-022-17775-y

Ejemplares similares